Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Lido Advisors LLC

Lido Advisors LLC increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 351.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,112 shares of the medical research company's stock after buying an additional 18,772 shares during the quarter. Lido Advisors LLC's holdings in Exact Sciences were worth $1,355,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its stake in Exact Sciences by 74.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,760,241 shares of the medical research company's stock valued at $323,669,000 after purchasing an additional 2,462,165 shares in the last quarter. Capital World Investors boosted its holdings in shares of Exact Sciences by 10.7% in the fourth quarter. Capital World Investors now owns 17,537,617 shares of the medical research company's stock valued at $985,439,000 after buying an additional 1,696,321 shares during the period. Norges Bank bought a new stake in shares of Exact Sciences during the fourth quarter worth $50,625,000. T. Rowe Price Investment Management Inc. lifted its position in Exact Sciences by 25.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,269,823 shares of the medical research company's stock valued at $239,922,000 after acquiring an additional 876,985 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Exact Sciences during the fourth quarter worth about $21,251,000. 88.82% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on EXAS shares. Robert W. Baird increased their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Benchmark reaffirmed a "buy" rating and set a $65.00 price objective on shares of Exact Sciences in a research report on Monday, January 13th. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Guggenheim reissued a "buy" rating and issued a $60.00 target price on shares of Exact Sciences in a research report on Friday, April 11th. Finally, Mizuho began coverage on shares of Exact Sciences in a research report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price target for the company. Two analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded up $0.19 during mid-day trading on Thursday, hitting $53.47. 404,535 shares of the company's stock traded hands, compared to its average volume of 2,646,655. The company has a market capitalization of $10.09 billion, a P/E ratio of -9.58 and a beta of 0.92. The company's 50-day moving average is $45.36 and its two-hundred day moving average is $53.07. Exact Sciences Co. has a 1 year low of $39.97 and a 1 year high of $72.83. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. During the same period in the previous year, the company earned ($0.60) EPS. The firm's quarterly revenue was up 10.9% on a year-over-year basis. On average, equities analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.